Amarin Corp Plc (AMRN)

[north40000]

Vascepa would sell like hotcakes in the U.S. if we shareholders can get the generics out of our hair.

Time to organize. Barron’s arrived today, dated 10/14/2024. The cover story: “Hidden Drug Deals— Confidential documents shed new light on the gatekeepers known as pharmacy-benefit managers—and their role in the opioid crisis” Page 16.
https://www.barron’s.com/hiddendrugdeals. If that doesn’t work, a platform search with selected keywords, author is Catharine Dunn, might work on Monday.

The 2-page story revolves around FTC and its chair Lina Khan being sued by Express Scripts and CVS/Caremark in Missouri District Court, and the manufacturer rebate system that has managed to create high drug profits for PBMs. In our case, the manufacturers are the generics who have cut a deal with PBMs that has resulted for me in a much higher drug price at CVS for brand Vascepa. That Amarin loss of contract bid was enabled by the collusive, deceptive, fraud on the Court that put two generics in the SHTG and off-label CVD markets in the 1st place, contrary to Hazel-Atlas, 322 U.S. 238(1944) and FRCP Rule 60 provisions.

Do we need to send to Khan anything more than a email link to our SH petition for writ of certiorari in the Supreme Court? CC to DOJ and SEC? I think I can personally take my copy to local FTC enforcement attorneys who will be responsible for answering the Missouri Complaint, and defending FTC in the Missouri Court. I would offer to be a fact witness for FTC in Missouri. How about a link to the recent CAFC opinion that reversed the Delaware District Court?